Comanche Biopharma raised an additional $40 million to fund human testing of its investigational siRNA injectable for preeclampsia, aiming to move the program into multiple clinical sites. The company framed the financing as enabling first‑in‑human trials for what could be a potential first therapy specifically targeting preeclampsia, a condition with high maternal and fetal risk and limited therapeutic options. Management said the capital will support regulatory and clinical execution as the program advances toward readouts.